发明公开
- 专利标题: PLASMA KALLIKREIN INHIBITORS
-
申请号: US18043357申请日: 2021-09-09
-
公开(公告)号: US20230416227A1公开(公告)日: 2023-12-28
- 发明人: Anthony Ken Ogawa , Christopher J. Sinz , Jacqueline D. Hicks , Alan C. Cheng , Song Yang , Jianming Bao , Donna A. A. W. Hayes , Simon B. Lang , Maoqun Tian , Salman Jabri , Galen Paul Shearn-Nance , Rongze Kuang , Zhiqiang Zhao , Zhicai Wu
- 申请人: Merck Sharp & Dohme LLC , Anthony Ken OGAWA , Christopher J. SINZ , Jacqueline D. HICKS , Alan C. CHENG , Song YANG , Jianming BAO , Donna A. A. W. HAYES , Simon B. LANG , Maoqun TIAN , Salman JABRI , Galen Paul SHEARN-NANCE , Rongze KUANG , Zhiqiang ZHAO , Zhicai WU
- 申请人地址: US NJ Rahway
- 专利权人: Merck Sharp & Dohme LLC
- 当前专利权人: Merck Sharp & Dohme LLC
- 当前专利权人地址: US NJ Rahway
- 国际申请: PCT/US2021/049545 2021.09.09
- 进入国家日期: 2023-02-28
- 主分类号: C07D401/14
- IPC分类号: C07D401/14 ; A61K45/06 ; A61P9/10
摘要:
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
信息查询